A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)

Trial Profile

A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Birinapant (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2017 Planned End Date changed from 30 Nov 2020 to 1 Feb 2021.
    • 05 Dec 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020.
    • 05 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top